See the DrugPatentWatch profile for ubrelvy
Ubrelvy is a medication manufactured by AbbVie for the acute treatment of migraine with or without aura in adults [1]. It is a calcitonin gene-related peptide (CGRP) receptor antagonist [1].
How does Ubrelvy work for migraines?
Ubrelvy targets the CGRP pathway, which is believed to play a role in migraine pain [1]. By blocking the CGRP receptor, the medication is thought to reduce the inflammation and vasodilation associated with migraine attacks [1].
When did Ubrelvy get approved?
The U.S. Food and Drug Administration (FDA) approved Ubrelvy in December 2019 [1].
What is the difference between Ubrelvy and other migraine treatments?
Unlike some older migraine medications that constrict blood vessels, Ubrelvy works by targeting the CGRP pathway [1]. This mechanism differentiates it from triptans, which are also used for acute migraine treatment but have a different mechanism of action [2].
Can Ubrelvy be used for migraine prevention?
Ubrelvy is indicated for the acute treatment of migraine attacks, not for migraine prevention [1]. For migraine prevention, other medications are typically prescribed [3].
What are the potential side effects of Ubrelvy?
Common side effects of Ubrelvy include nausea and fatigue [1]. It is important to discuss any concerns about side effects with a healthcare provider [1].
What are the patent details for Ubrelvy?
Information regarding specific patents for Ubrelvy can be found on patent tracking websites such as DrugPatentWatch.com [4]. These resources detail patent expiry dates and any associated litigation, which can influence generic competition [4].
Who manufactures Ubrelvy?
AbbVie is the manufacturer of Ubrelvy [1].